Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 2/20 | 0.44 |
| ▸ | FNTB | P49356 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 16/20 | 0.42 |
| ▸ | CA2 | P00918 | 16/20 | 0.42 |
| ▸ | CA9 | Q16790 | 15/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 5/20 | 0.40 |
| ▸ | CA7 | P43166 | 5/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.40 |
| ▸ | CA3 | P07451 | 4/20 | 0.40 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA6 | P23280 | 4/20 | 0.40 |
| ▸ | CA5A | P35218 | 4/20 | 0.40 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6049745 | 0.97 | FNTA (0.47) | FNTAFNTBCA1CA2CA9 | |
| SCHEMBL11399677 | 0.97 | FNTA (0.47) | FNTAFNTBCA1CA2CA9 | |
| SCHEMBL211160 | 0.97 | FNTA (0.47) | FNTAFNTBCA1CA2CA9 | |
| SCHEMBL20275856 | 0.97 | FNTA (0.47) | FNTAFNTBCA1CA2CA9 | |
| SCHEMBL11587906 | 0.97 | FNTA (0.47) | FNTAFNTBCA1CA2CA9 | |
| Ammonia Solution, Strong SCHEMBL11352454 | 0.97 | FNTA (0.43) | FNTAFNTBCA1CA2CA9 | |
| 1,4-Butanediol SCHEMBL16468151 | 0.97 | FNTA (0.47) | FNTAFNTBCA1CA2CA9 | |
| Ammonia Solution, Strong SCHEMBL5665446 | 0.95 | FNTA (0.46) | FNTAFNTBCA1CA2CA9 | |
| SCHEMBL710961 | 0.92 | — | — | |
| Ethylene Glycol SCHEMBL445777 | 0.92 | FNTA (0.46) | FNTAFNTBCA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 291 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-220209012-U | Battery pole piece and winding battery | 微宏动力系统（湖州）有限公司 | 2023-12-19 | — | — | CN | claimed |
| CN-117012895-A | Battery pole piece, winding battery and preparation method thereof | 微宏动力系统（湖州）有限公司 | 2023-11-07 | — | — | CN | claimed |
| CN-116031482-A | Secondary battery electrolyte, preparation method thereof, secondary battery and electronic equipment | 华为终端有限公司 | 2023-04-28 | — | — | CN | claimed |
| CN-112225719-B | Synthetic method of cyclic sulfate | 湖南阿斯达新材料有限公司 | 2022-08-05 | — | — | CN | claimed |
| CN-111864275-B | Battery cell, preparation method thereof and lithium ion battery | 北京卫蓝新能源科技有限公司 | 2021-10-15 | — | — | CN | claimed |
| CN-108258312-B | Non-aqueous electrolyte of high-voltage lithium ion battery | 珠海市赛纬电子材料股份有限公司 | 2021-05-11 | — | — | CN | claimed |
| CN-112225719-A | Synthetic method of cyclic sulfate | 湖南阿斯达新材料有限公司 | 2021-01-15 | — | — | CN | claimed |
| CN-111864275-A | Battery cell, preparation method thereof and lithium ion battery | 北京卫蓝新能源科技有限公司 | 2020-10-30 | — | — | CN | claimed |
| EP-2437340-B1 | NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY AND METHOD FOR PRODUCING THE SAME | GS YUASA INT LTD (JP) | 2016-03-23 | — | — | EP | claimed |
| CN-102439777-B | Nonaqueous electrolyte secondary battery and method for manufacturing nonaqueous electrolyte secondary battery | GS YUASA INT LTD | 2014-07-30 | — | — | CN | claimed |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2011-01-06 | — | — | US | claimed |
| EP-1064013-A4 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2005-05-11 | — | — | EP | claimed |
| US-20040110068-A1 | Lithium secondary cell | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-06-10 | — | — | US | claimed |
| EP-1406338-A1 | LITHIUM SECONDARY CELL | MITSUBISHI CHEMICAL CORPORATION (JP) | 2004-04-07 | — | — | EP | claimed |
| US-20030108595-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY AT KINGSTON | 2003-06-12 | — | — | US | claimed |
| US-20010048941-A1 | Method for treating amyloidosis | QUEEN'S UNIVERSITY OF KINGSTON | 2001-12-06 | — | — | US | claimed |
| EP-1064013-A1 | $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | University of Washington (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045947-A9 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIV WASHINGTON (US) | 2000-03-02 | — | — | WO | claimed |
| WO-1999045947-A1 | IN VITRO FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES | UNIVERSITY OF WASHINGTON (US) | 1999-09-16 | — | — | WO | claimed |
| US-5643562-A | ANTIDEPOSIT AGENTS FOR PROTEINS FOR MEDICAL DIAGNOSIS OF DISEASES | QUEEN'S UNIVERSITY OF KINGSTON (CA) | 1997-07-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108595-A1 | Method for treating amyloidosis | TTR, IAPP, APP | FNTA 2106/4885FNTB 1864/4885CA1 438/4885 |
| US-20010048941-A1 | Method for treating amyloidosis | TTR, APOB, NEFM | FNTA 1816/4885FNTB 1612/4885CA1 366/4885 |
| US-20110002875-A1 | METHOD FOR TREATING AMYLOIDOSIS | TTR, IAPP, APP | FNTA 2106/4885FNTB 1864/4885CA1 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.